ZHAO, XIANGLIN,XIONG, JING,LIAO, LV,RIPOCHE, SEBASTIEN,NIMSGERN, PIERRE,MAH, ROBERT,LEBLANC, CATHERINE,KNOPFEL, THOMAS,FURET, PASCAL,FAIRHURST, ROBIN ALEC,BUSCHMANN, NICOLE,WANG, CAN,HAN, BO
申请号：
PE0005342016
公开号：
PE05462016A1
申请日:
2014.10.24
申请国别(地区):
PE
年份:
2016
代理人:
摘要：
The present Invention relates to a compound of formula (i), which inhibit the fgfr4 for Cancer Treatment, particularly the treatment of liver cancer. Where: V is CH2, etc W is CH2, ch2ch2 or link X is C (RX) or N and C (RX) or N Z is n or CH, RX is Hydrogen, halogen, etc. R is Hydrogen, halogen, etc. r1 is Hydrogen, halogen, etc.Preferred compounds are n - (5 - cianopiridin IL - 2 - 7) - formyl 3,4 dihydro - 1.8 - naftiridina - 1 - (2H) - carboxamide n - (2 - 4.5 - cloropiridin - il) - 7 - formyl - 3,4-dihydro - 1.8 - naftiridina - (2H) - 1 - carboxamide among others.La presente invencion se refiere a un compuesto de la formula (I) que inhiben el FGFR4 para el tratamiento de cancer, particularmente el tratamiento de cancer hepatico. Donde: V es CH2, O, etc. W es CH2, CH2CH2 o enlace X es C(Rx) o N Y es C(Rx) o N Z es CH o N Rx es hidrogeno, halogeno, etc. Ry es hidrogeno, halogeno, etc. R1 es es hidrogeno, halogeno, etc. Son compuestos preferidos N-(5-cianopiridin-2-il)-7-formil-3,4-dihidro-1,8-naftiridina-1-(2H)-carboxamida N-(4,5-cloropiridin-2-il)-7-formil-3,4-dihidro-1,8-naftiridina-1-(2H)-carboxamida entre otros.
